Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ · Healthcare
Madrigal Pharmaceuticals, Inc. Shareholder Equity 2012–2025
Madrigal Pharmaceuticals, Inc. annual shareholder equity history from 2012 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- Madrigal Pharmaceuticals, Inc. shareholder equity as of December 31, 2025: 602.7M, a 20.11% decrease year-over-year.
- Madrigal Pharmaceuticals, Inc. shareholder equity for 2025 were 602.7M, a 20.11% decrease from 2024.
- Madrigal Pharmaceuticals, Inc. shareholder equity for 2024 were 754.4M, a 86.11% increase from 2023.
- Madrigal Pharmaceuticals, Inc. shareholder equity for 2023 were 405.3M, a 105.35% increase from 2022.
- Madrigal Pharmaceuticals, Inc. shareholder equity for 2022 were 197.4M.
Shareholder Equity
ANNUAL · $B
YEAR-OVER-YEAR GROWTH · %
| Madrigal Pharmaceuticals, Inc. Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $603 |
| 2024 | $754 |
| 2023 | $405 |
| 2022 | $197 |
| 2021 | $196 |
| 2020 | $240 |
| 2019 | $417 |
| 2018 | $477 |
| 2017 | $182 |
| 2012 | $75 |
Madrigal Pharmaceuticals, Inc. Shareholder Equity — FAQ
Madrigal Pharmaceuticals, Inc. (MDGL) shareholder equity over the last 10 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see MDGL's shareholder equity history?
The chart and table above show Madrigal Pharmaceuticals, Inc.'s shareholder equity by year and by quarter, including the growth rate.